Describe the epidemiology and neurobiology of GAD, including the main circuits and neurotransmitters implicated in the disorder and its frequent comorbidity with MDD Assess patients for GAD according to DSM-5-TR diagnostic criteria, differentiating it from normal worry/anxiety and other psychiatric and medical conditions with similar presentations Evaluate unmet needs associated with current treatment strategies and the therapeutic potential of investigational psychedelics for GAD, according to their MOAs and recent clinical data
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership · $99–598/yr
| New Membership – Standard | $349/yr |
| New Membership – Standard (2-year) | $598/yr |
| New Membership – Military/VA | $259/yr |
| New Membership – Student/Resident | $149/yr |
| Renewal Membership – Standard | $249/yr |
| Renewal Membership – Standard (2-year) | $478/yr |
+27 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Child & Adolescent Psychiatry
- Clinical Informatics
- Communication & Shared Decision-Making
- General & Adult Psychiatry
- General Surgery
- Interventional Radiology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Nuclear Medicine
- Pain Medicine
- Pediatric Neurology
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Sleep Medicine
- Cross-Specialty
- Medical Subspecialties
- Neurology
- Pain & Palliative
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- On-demand / recorded video
- Credit · Up to 1 credit
- MOC · Up to 1 point
- Commercial Support
-
ReleasedJul 6, 2026
-
Last day to claim creditJul 7, 2027 9 months left
-
Neuroscience Education Institute +1 Fast and Curious: Exciting Advances in the Rapid-Acting and Targeted Treatment of Major Depressive Disorder
-
HMP Education Novel Strategies for Treatment-Resistant Depression : Understanding the Utility of Glutamatergic Antidepressants
-
HMP Education Antidepressants for Older Adults with MDD: Integrating Clinical and Real-World Evidence with Patient-Specific Considerations to Optimize Outcomes
